閻 雲

Medicine & Life Sciences

1. Neoplasms 59%
2. ribonucleotide reductase M2 44%
3. Breast Neoplasms 34%
4. IT-101 27%
5. gemcitabine 27%
6. Hydroxyurea 22%
7. KB Cells 21%
8. Hepatocellular Carcinoma 21%
9. Biomarkers 17%
10. Therapeutics 17%
11. GTI2040 17%
12. DNA Damage 16%
13. Growth 16%
14. Cholangiocarcinoma 15%
15. Colorectal Neoplasms 14%
16. Small Interfering RNA 14%
17. Genes 14%
18. 3-aminopyridine-2-carboxaldehyde thiosemicarbazone 14%
19. Camptothecin 14%
20. DNA Repair 14%
21. Survival 13%
22. MPT0L145 13%
23. Cell Line 13%
24. Drug Therapy 13%
25. Neoplasm Metastasis 13%
26. Receptor, Fibroblast Growth Factor, Type 3 12%
27. Pharmacokinetics 12%
28. Carcinogenesis 12%
29. In Vitro Techniques 11%
30. Cell Proliferation 11%
31. Liver Neoplasms 11%
32. Messenger RNA 11%
33. Clone Cells 10%
34. Proteins 10%
35. Heterografts 10%
36. Stem Cells 10%
37. MicroRNAs 10%
38. Bortezomib 10%
39. Nanoparticles 9%
40. Autophagy 9%
41. DNA 9%
42. Gene Expression 9%
43. Maximum Tolerated Dose 9%
44. Non-Small Cell Lung Carcinoma 8%
45. Arginine 8%
46. PHY 906 8%
47. cyclodextrin polymer 8%
48. Triple Negative Breast Neoplasms 8%
49. Apoptosis 8%